Cancer NetworkOriginal article
<![CDATA[RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs]]>
Phase 3positiveRYZ101Positive
AI Analysis
Summary
RYZ101 demonstrated improved progression-free survival in previously treated GEP-NETs in the Phase 3 ACTION-1 trial. Investigators will continue patient follow-up to assess overall survival outcomes.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
RYZ101 improved progression-free survival in previously treated GEP-NETs
Importance:7/10
Sentiment:
0.75
Phase 3 trialpositive dataoncologyneuroendocrine tumorsprogression-free survival
Read the original article
Published by Cancer Network on October 12, 2026 2:30 PM